Clinical Trials Browser

Recurrence × N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide × Clear all

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05951855 2023-07-19

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase 2 Unknown

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05527275 2022-09-02

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1/2 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03245905 2021-03-16

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Phase 2 Unknown

Recurrence, Lymphoma, B-Cell

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03321890 2017-10-26

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral